This case uses OCH1-engineered Pichia pastoris to secrete recombinant alpha-1 antitrypsin with homogeneous N-glycans.
Ir-CPI polypeptide inhibits Factor XIIa and kallikrein activity to block thrombus formation without impairing primary hemostasis.
Transgenic mouse model lacking hepatic and circulatory AAT protein enables therapeutic compound screening.